Oxford Cannabinoid Technologies Holdings PLCFRA Oxford Cannabinoid Stock Report

Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company that specializes in cannabinoid drug development with focus on the pain market. The firm is developing a portfolio of prescription cannabinoid medicines (pCBs). The firm has established a pipeline of three types of cannabinoid compounds, from which it is developing medicines that target the endocannabinoid system. The cannabinoid compounds include Phytocannabinoids, the same compounds found in cannabis (pCBs); Chemically modified pCBs with improved drug-like characteristics, and; Novel chemical entities (NCEs) with cannabinoid receptor selectivity. Its pipeline program includes OCT461201, OCT130401 and cannabinoid derivatives. The company targets drug development in neuropathic and visceral pain, focusing on chemotherapy-induced peripheral neuralgia (CIPN), irritable bowel syndrome (IBS) and trigeminal neuralgia. The firm's subsidiary is Oxford Cannabinoid Technologies Ltd.